3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
62
Thoracic
4
Tumor-Agnostic
3
Gynecologic
3
Other solid neoplasm
2
Dermatologic
2
Breast
2
NET
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
Everolimus
18
lutetium Lu 177 dotatate
9
lanreotide
8
surufatinib
7
Octreotide
7
pasireotide
5
amino-acid, glucose, and electrolyte solution
5
Sunitinib
5
Temozolomide
4
Data Collection
4
pembrolizumab
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
tislelizumab
2
fosbretabulin
2
arginyllysine
2
anlotinib
2
Paclitaxel
2
PM 01183
2
Lutetium-177
2
Lutetium
2
Irinotecan
2
Injections
2
Carboplatin
2
64Cu-SARTATE
2
3-Iodobenzylguanidine
2
toripalimab
1
telotristat ethyl
1
taxane
1
repotrectinib
1
pralsetinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Folfox protocol
×
NET
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled